ORIGINAL ARTICLE
Sarcoma – correlation between CD73 and PD-L1 and their relationship with prognosis
 
More details
Hide details
1
Department of Medical Oncology, Adana City Education and Research Hospital, Adana, Turkey
 
2
Department of Oncology, Çukurova University Faculty of Medicine, Adana, Turkey
 
3
Department of Pathology, Çukurova University Faculty of Medicine, Adana, Turkey
 
4
Adana Private Hospital, Adana, Turkey
 
5
Department of Physical Medicine and Rehabilitation, Çukurova University Faculty of Medicine, Adana, Turkey
 
 
Submission date: 2022-03-20
 
 
Final revision date: 2022-11-17
 
 
Acceptance date: 2022-11-20
 
 
Publication date: 2023-03-06
 
 
Corresponding author
Ayşegül Yetişir
Abdullah Evren Yetişir, MD Department of Medical Oncology Adana City Education and Research Hospital Adana, Turkey
 
 
Pol J Pathol 2022;73(4):338-342
 
KEYWORDS
TOPICS
ABSTRACT
This study aimed to evaluate CD73 and PD-L1 and determine their relationship with each other and with overall survival (OS) in sarcoma patients.
The paraffin blocks of 101 patients were analysed. 56.4% were female, and the mean age was 51.39 years. The mean OS was 20.73 months, and the Ki-67 proliferative index was 41.45. A positive correlation was found between CD73 tumour and CD73 tumour-infiltrating lymphocyte (TIL) findings. CD73 tumour and TIL findings were also positively correlated with PD-L1 percentages and PD-L1 intensity.
An inverse correlation was detected between OS and CD73 tumour and TIL groups of 5–25%, 25–50%, 50–75%, 75–90%, and > 90%, but no such correlation was found for the ≤ 5% group. There was an inverse correlation between OS and the PD-L1 percentages of <10% and > 50% and the PD-L1 intensity of weak-moderate and strong, but no correlation was found for the negative values. Lastly, an inverse correlation was found between OS and the Ki-67 proliferative index.
We found CD73 and PD-L1 positivity to be associated with decreased OS in sarcoma patients and determined a significant correlation between these parameters. This result is promising in terms of achieving better survival and disease control with anti-CD73 and anti-PD-L1 therapy in selected patients.
REFERENCES (15)
1.
McClay EF. Epidemiology of bone and soft tissue sarcomas. Sem Oncol 1989; 16: 264-272.
 
2.
Hoefkens F, Dehandschutter C, Somville J, et al. Soft tissue sarcoma of the extremities: pending questions on surgery and radiotherapy. Rad Oncol 2016; 11: 136.
 
3.
Bourcier K, Le Cesne A, Tselikas L, et al. Basic knowledge in soft tissue sarcoma. Cardiovasc Intervent Radiol 2019; 42: 1255-1261.
 
4.
Sbaraglia M, dei Tos AP. The pathology of soft tissue sarcomas. Radiol Med 2019; 124: 266-281.
 
5.
Liu W, Jiang Q, Zhou Y. Advances of systemic treatment for adult soft-tissue sarcoma. Chin Clin Oncol 2018; 7: 42.
 
6.
Tukiainen E, Böhling T, Huuhtanen R. Soft tissue sarcoma of the trunk and extremities. Scand J Surg 2003; 92: 257-263.
 
7.
Ono K, Shiozawa E, Ohike N, et al. Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: a retrospective study of 136 patients. Oncol Lett 2018; 15: 2123-2130.
 
8.
Turcotte M, Spring K, Pommey S, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res 2015; 75: 4494-4503.
 
9.
Meng X, Huang Z, Teng F, et al. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 2015; 41: 868-876.
 
10.
Paydas S, Bagir EK, Deveci MA, et al. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol 2016; 33: 93.
 
11.
Skubitz KM, D’Adamo DR. Sarcoma. Mayo Clin Proc 2007; 82: 1409-1432.
 
12.
Buisseret L, Pommey S, Allard B, et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol 2018; 29: 1056-1062.
 
13.
Morello S, Capone M, Sorrentino C, et al. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med 2017; 15: 244.
 
14.
Engellau J, Akerman M, Anderson H, et al. Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl Immunohistochem Mol Morphol 2001; 9: 358-363.
 
15.
Lee JH, Yoon YC, Seo SW, et al. Soft tissue sarcoma: DWI and DCE-MRI parameters correlatewith Ki-67 labeling index. Eur Radiol 2020; 30: 914-924.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top